ATE288960T1 - Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 - Google Patents

Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Info

Publication number
ATE288960T1
ATE288960T1 AT98910057T AT98910057T ATE288960T1 AT E288960 T1 ATE288960 T1 AT E288960T1 AT 98910057 T AT98910057 T AT 98910057T AT 98910057 T AT98910057 T AT 98910057T AT E288960 T1 ATE288960 T1 AT E288960T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
humanized monoclonal
high affinity
affinity against
against day
Prior art date
Application number
AT98910057T
Other languages
English (en)
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE288960T1 publication Critical patent/ATE288960T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98910057T 1998-02-25 1998-02-25 Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 ATE288960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003679 WO1999043816A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE288960T1 true ATE288960T1 (de) 2005-02-15

Family

ID=22266462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910057T ATE288960T1 (de) 1998-02-25 1998-02-25 Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Country Status (9)

Country Link
EP (1) EP1056860B1 (de)
JP (1) JP4080692B2 (de)
AT (1) ATE288960T1 (de)
AU (1) AU758358B2 (de)
CA (1) CA2321932A1 (de)
DE (1) DE69829001T2 (de)
IL (1) IL138021A0 (de)
NO (1) NO20004250L (de)
WO (1) WO1999043816A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1127148B1 (de) * 1998-10-31 2012-08-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Varianten des humanisierten monoklonalen anti-krebs antikörpers cc49
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2003248744C1 (en) 2002-06-28 2009-12-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
DK1877102T3 (da) 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
SG162726A1 (en) * 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2935520B2 (ja) * 1988-10-19 1999-08-16 ザ ダウ ケミカル カンパニー ガン治療に用いられる新規高親和性改変抗体系統群

Also Published As

Publication number Publication date
EP1056860B1 (de) 2005-02-09
AU6439398A (en) 1999-09-15
IL138021A0 (en) 2001-10-31
DE69829001T2 (de) 2006-03-23
EP1056860A1 (de) 2000-12-06
CA2321932A1 (en) 1999-09-02
WO1999043816A1 (en) 1999-09-02
JP4080692B2 (ja) 2008-04-23
AU758358B2 (en) 2003-03-20
NO20004250D0 (no) 2000-08-24
DE69829001D1 (de) 2005-03-17
NO20004250L (no) 2000-10-24
JP2002504371A (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
EA200800094A1 (ru) Антитела cd19 и их использование
CY1121173T1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
BR0311792A (pt) Anticorpo de receptor anti-igf-i
ATE317437T1 (de) Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
EP1585966B8 (de) Behandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4
IN2009KN02404A (de)
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL291545B1 (en) Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
BG101024A (bg) Моноклонално антитяло срещу сd44v6
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
GR3026219T3 (en) Mouse monoclonal antibodies
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
WO2003064593A3 (en) Antigen panels and methods of using the same
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
EA200601405A1 (ru) Гуманизированное антитело

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties